Sun Pharma Announces US FDA Acceptance Of Supplemental Biologics License (Sbla) Application For ILUMYA® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic ...

Sun Pharma Announces US FDA Acceptance Of Supplemental Biologics License (Sbla) Application For ILUMYA® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis. If the sBLA is ...
JD Supra

Sun Pharma Launches ILUMYA® in India

On December 1, 2025, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) announced the launch of ILUMYA® (tildrakizumab-asmn) in India. ILUMYA® is a humanized monoclonal antibody injection indicated for ...

Sun Pharmaceutical Industries Inc., USA (Sun Pharma): Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA (tildrakizumab-asmn ...

If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...
KELOLAND News

ILUMYA® (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference

Patients treated with ILUMYA demonstrated a significantly higher rate of 75% improvement from baseline in the Nail Psoriasis Severity Index (mNAPSI 75) at Week 28 (25.5% mNAPSI 75 response rate vs.
Pharmabiz

US FDA accepts Sun Pharma’s sBLA for Ilumya to treat adults with active psoriatic arthritis

Our Bureau, Mumbai Tuesday, March 17, 2026, 10:30 Hrs [IST] ...